ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO691

CD11b Activation Reduces Inflammation in Lupus Nephritis by Downregulating TLR Pathways

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Khan, Samia, Rush University Medical Center, Chicago, Illinois, United States
  • Faridi, Mohd Hafeez, Rush University Medical Center, Chicago, Illinois, United States
  • Lee, Ha Won, Rush University Medical Center, Chicago, Illinois, United States
  • Altintas, Mehmet M., Rush University Medical Center, Chicago, Illinois, United States
  • Khaliqdina, Shehryar J., Rush University Medical Center, Chicago, Illinois, United States
  • Cimbaluk, David J., Rush University Medical Center, Chicago, Illinois, United States
  • Gupta, Vineet, Rush University Medical Center, Chicago, Illinois, United States
Background

Single nucleotide polymorphisms (SNPs) in the ITGAM gene, coding for CD11b subunit of the integrin CD11b/CD18, produce defective protein and confers a strong predisposition to systemic lupus erythematosus (SLE, lupus) and lupus nephritis. Elevated levels of IFN I in circulation is a heritable risk factor for SLE and play a pathogenic role and are likely driven by a combination of genetic variations and environmental stress. Here we investigate if variations in ITGAM are linked to high IFN I and whether pharmacological CD11b activation could be a therapeutic strategy.

Methods

To test for a direct link between ITGAM SNPs and the TLR induced IFN-I pathways, we measured serum IFN I activity in 171 SLE patients and determined their ITGAM genotype. Since ITGAM SNPs result in functionally deficient CD11b, we tested whether partial CD11b activation with small molecule agonist, leukadherin-1 (LA1) can suppress IFN-I pathways and determined TLR signaling components that are regulated by CD11b activation. To test the efficacy of LA1 in a lupus model, we used the MRL/lpr mice that develop IFN I-dependent multi-organ lupus similar to human lupus with renal inflammation.

Results

We report that SLE subjects carrying ITGAM SNPs have significantly elevated serum IFN-I activity indicating a direct link between reduced CD11b activity and elevated inflammation in patients. LA1 treatment reduced IFN I responses and protected lupus-prone MRL/lpr mice from kidney injury. LA1-treated mice had reduced glomerular damage, proteinuria, and IgG renal immune complex deposition as compared to vehicle-treated controls. CD11b agonist LA1 suppressed proinflammatory cytokine secretion by TLR-activated leukocytes and suppressed IFN I signaling, via an AKT-FOXO3-IRF7 pathway. TLR-stimulated macrophages from CD11b SNP carriers showed increased expression of IRF7 and IFNB, as well as increased nuclear exclusion of FOXO3, which was reversed by LA1.

Conclusion

LA1 suppresses TLR-induced cytokine production that has been directly linked to exacerbation of lupus nephritis. Hence pharmacological CD11b activation is a promising potential novel therapeutic target, particularly in patients identified as carriers of ITGAM variants.

Funding

  • NIDDK Support